Home | Careers | Contact Us About Us Therapeutic Focus Firdapse™ Expanded Access Pipeline Business Development Investors News & Events Welcome Print Share Catalyst Pharmaceutical Partners Inc. (Catalyst Pharmaceuticals), is a biopharmaceutical company focused on developing and commercializing innovative therapies for people with rare debilitating diseases. Catalyst's lead program, Firdapse™, is currently in the late stages of a pivotal phase III, global, multi-centered trial for the treatment of patients with Lambert - Eaton Myasthenic Syndrome (LEMS). LEMS is a rare autoimmune disorder with the primary symptoms of debilitating muscle weakness, where the immune system attacks the nerves that control the muscles. Firdapse™ Expanded Access Program Catalyst Pharmaceuticals has announced the initiation of the Firdapse™ Expanded Access Program which is a Phase IV open label study where pateints who are diagnosed with LEMS and meet the inclusion and exclusion criteria can receive Firdapse™ (at no cost) when a patient's physician feels Firdapse™ can help improve his or her condition. Read More Pipeline Catalyst Pharmaceuticals is also studying Firdapse™ in other neurological orphan indications including Congenital Myasthenic Syndrome (CMS), and Downbeat Nystagmus. Other pipeline programs include CPP-115, which is under investigation in several neurological conditions such as post- traumatic stress disorders, Tourette’s disorders and infantile spasms. Read More Patient Advocacy Some of the numerous Advocacy Organizations which Catalyst is working with to help people with rare diseases include: Neuropathy Association www.neuropathy.org Dysautonomia international www.dysautonomiainternational.org National Organization for Rare Disorders (NORD) www.rarediseases.org What’s New? Sept 4, 2014 — Catalyst Pharmaceuticals Appoints David D. Muth as Executive Vice President, Corporate Development... Read More Sept 3, 2014 — Catalyst Pharmaceutical Partners to Present at Rodman & Renshaw's 16th Annual Global Investment Conference... Read More Sept 2, 2014 — Catalyst Pharmaceutical Partners Initiates Phase 1(b) Safety and Tolerance Study for CPP-115... Read More Aug 14, 2014 — Catalyst Pharmaceutical Partners Announces Second Quarter 2014 Financial Results... Read More Aug 11, 2014 — Catalyst Pharmaceutical Partners Provides Updates on Progress of Phase 3 Firdapse Study in Patients With Lambert-Eaton Myasthenic Syndrome (LEMS)... Read More June 18, 2014 — Catalyst Pharmaceutical Partners Set to Join Russell Microcap(R) Index... Read More May 16, 2014 — Catalyst Pharmaceutical Partners Announces First Quarter 2014 Financial Results and Provides Corporate Update... Read More © 2021 CatalystPharma | Privacy Policy | Site Map | Webmail login Website by Axxiem